Grand Rounds Nation®

The vast majority of US adults consume more than double the recommended maximum of sodium, which is a direct cause of hypertension, a condition that affects nearly 1 in 3 Americans. Hypertension is not only a major contributor to cardiovascular disease (CVD), disability, and health disparities, but the treatment of related CVDs can cost our already overburdened health system $273 billion annually.

Sadly, the public does not always have a choice when it comes to reducing sodium intake: we cannot remedy this problem simply by removing the salt shaker from our tables. Of the 3,400 mg of sodium the average American consumes daily, nearly 80% is invisible in sources such as restaurant and processed foods. And once the salt is in the food, it cannot be taken out!

This session of Public Health Grand Rounds explored the consequences of excessive sodium intake and discussed the technological context for the use of salt in our food supply. The speakers reviewed current sodium control efforts, such as the National Salt Reduction Initiative and food procurement policies, and separated fact from fiction to support actions needed to address this very real public health burden.

This is Part 2 of a lecture in three …

The vast majority of US adults consume more than double the recommended maximum of sodium, which is a direct cause of hypertension, a condition that affects nearly 1 in 3 Americans. Hypertension is not only a major contributor to cardiovascular disease (CVD), disability, and health disparities, but the treatment of related CVDs can cost our already overburdened health system $273 billion annually.

Sadly, the public does not always have a choice when it comes to reducing sodium intake: we cannot remedy this problem simply by removing the salt shaker from our tables. Of the 3,400 mg of sodium the average American consumes daily, nearly 80% is invisible in sources such as restaurant and processed foods. And once the salt is in the food, it cannot be taken out!

This session of Public Health Grand Rounds from the CDC explored the consequences of excessive sodium intake and discussed the technological context for the use of salt in our food supply. The speakers reviewed current sodium control efforts, such as the National Salt Reduction Initiative and food procurement policies, and separated fact from fiction to support actions needed to address this very real public health burden.

This is Part 1 of a …

For people who carry genetic predispositions toward Alzheimer's Disease, little is currently known about predicting the onset, course, and severity of disease at the individual level. However, because cogntitive degenerative diseases most often follow a gradual course of symptom progression later in life, medical professionals must be aware of the distinct, discoverable changes that occur at the "preclinical" stage, i.e prior to the symptomatic onset of memory loss.

In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about Alzheimer's Disease from an unique perspective of the preclinical stage. From classical signs on physicial exam to emerging biomolecular lab tests and novel imaging modalities, the pathophysiologic changes underlying Alzheimer's Disease are explored in depth.

Presenting this session of Grand Rounds is Dr. Richard Caselli, behavioral neurologist and professor of neurology at the Mayo Clnic in Scottsdale, Arizona.

This is Part 3 of a lecture in three parts.

Part 1 >>

Part 2 >>

To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.

For people who carry genetic predispositions toward Alzheimer's Disease, little is currently known about predicting the onset, course, and severity of disease at the individual level. However, because cogntitive degenerative diseases most often follow a gradual course of symptom progression later in life, medical professionals must be aware of the distinct, discoverable changes that occur at the "preclinical" stage, i.e prior to the symptomatic onset of memory loss.

In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about Alzheimer's Disease from an unique perspective of the preclinical stage. From classical signs on physicial exam to emerging biomolecular lab tests and novel imaging modalities, the pathophysiologic changes underlying Alzheimer's Disease are explored in depth.

Presenting this session of Grand Rounds is Dr. Richard Caselli, behavioral neurologist and professor of neurology at the Mayo Clnic in Scottsdale, Arizona.

This is Part 2 of a lecture in three parts.

Part 1 >>

Part 3 >>

To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.

For people who carry genetic predispositions toward Alzheimer's disease, little is currently known about predicting the onset, course, and severity of disease at the individual level. However, because cogntitive degenerative diseases most often follow a gradual course of symptom progression later in life, medical professionals must be aware of the distinct, discoverable changes that occur at the "preclinical" stage, i.e prior to the symptomatic onset of memory loss.

In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about Alzheimer's Disease from a unique perspective of the preclinical stage. From classical signs on physicial exam to emerging biomolecular lab tests and novel imaging modalities, the pathophysiologic changes underlying Alzheimer's disease are explored in depth.

Presenting this session of Grand Rounds is Dr. Richard Caselli, behavioral neurologist and professor of neurology at the Mayo Clnic in Scottsdale, Arizona.

This is Part 1 of a lecture in three parts.

Part 2 >>

Part 3 >>

To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.

For people who carry genetic predispositions toward Alzheimer's Disease, little is currently known about predicting the onset, course, and severity of disease at the individual level. However, because cogntitive degenerative diseases most often follow a gradual course of symptom progression later in life, medical professionals must be aware of the distinct, discoverable changes that occur at the "preclinical" stage, i.e prior to the symptomatic onset of memory loss.

In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about Alzheimer's Disease from an unique perspective of the preclinical stage. From classical signs on physicial exam to emerging biomolecular lab tests and novel imaging modalities, the pathophysiologic changes underlying Alzheimer's Disease are explored in depth.

Presenting this session of Grand Rounds is Dr. Richard Caselli, behavioral neurologist and professor of neurology at the Mayo Clnic in Scottsdale, Arizona.

This is Part 3 of a lecture in three parts.

Part 1 >>

Part 2 >>

To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.

For people who carry genetic predispositions toward Alzheimer's Disease, little is currently known about predicting the onset, course, and severity of disease at the individual level. However, because cogntitive degenerative diseases most often follow a gradual course of symptom progression later in life, medical professionals must be aware of the distinct, discoverable changes that occur at the "preclinical" stage, i.e prior to the symptomatic onset of memory loss.

In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about Alzheimer's Disease from an unique perspective of the preclinical stage. From classical signs on physicial exam to emerging biomolecular lab tests and novel imaging modalities, the pathophysiologic changes underlying Alzheimer's Disease are explored in depth.

Presenting this session of Grand Rounds is Dr. Richard Caselli, behavioral neurologist and professor of neurology at the Mayo Clnic in Scottsdale, Arizona.

This is Part 2 of a lecture in three parts.

Part 1 >>

Part 3 >>

To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.

For people who carry genetic predispositions toward Alzheimer's disease, little is currently known about predicting the onset, course, and severity of disease at the individual level. However, because cogntitive degenerative diseases most often follow a gradual course of symptom progression later in life, medical professionals must be aware of the distinct, discoverable changes that occur at the "preclinical" stage, i.e prior to the symptomatic onset of memory loss.

In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about Alzheimer's Disease from a unique perspective of the preclinical stage. From classical signs on physicial exam to emerging biomolecular lab tests and novel imaging modalities, the pathophysiologic changes underlying Alzheimer's disease are explored in depth.

Presenting this session of Grand Rounds is Dr. Richard Caselli, behavioral neurologist and professor of neurology at the Mayo Clnic in Scottsdale, Arizona.

This is Part 1 of a lecture in three parts.

Part 2 >>

Part 3 >>

To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.

The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB death rates have fallen by 35% since 1990, and as many as 6 million lives have been saved since 1995.

In spite of these successes, TB still remains a serious threat, especially for those infected with HIV. HIV is the single most powerful risk factor for TB disease and one of the leading causes of death among people infected with HIV. Among the 1.7 million lives that TB claimed in 2009, 380,000 were among people with HIV infection. While people with HIV who have TB can be effectively diagnosed and treated, more effort is needed to diagnose and treat TB promptly and effectively, and to scale-up preventive treatment for TB.

This special session of Public Health Grand Rounds shed light on myths and misconceptions about TB and HIV, and discussed actions needed in preventing deaths from this lethal combination.

This is Part 3 of a lecture in three parts.

Part 1 >>

Part …

The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB death rates have fallen by 35% since 1990, and as many as 6 million lives have been saved since 1995.

But in spite of these successes, TB still remains a serious threat, especially for those infected with HIV— the single most powerful risk factor for TB disease and one of the leading causes of death among people infected with HIV. Among the 1.7 million lives that TB claimed in 2009, 380,000 were among people with HIV infection. While people with HIV who have TB can be effectively diagnosed and treated, more effort is needed to diagnose and treat TB promptly and effectively, and to scale-up preventive treatment for TB.

This special session of Public Health Grand Rounds sheds light on myths and misconceptions about TB and HIV, and discusses actions needed in preventing deaths from this lethal combination.

This is Part 2 of a lecture in three parts.

Part 1 >>

Part …